Dr. Llamoso is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 E 84th St
Apt 15G
New York, NY 10028
Education & Training
Medical College of Wisconsin Affiliated HospitalsFellowship, Infectious Disease, 1997 - 1999
University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 1994 - 1997
Mathias Aznar Memorial College of MedicineClass of 1991
Certifications & Licensure
CA State Medical License 2000 - Present
NY State Medical License 2004 - 2024
WI State Medical License 1997 - 2005
IL State Medical License 1994 - 1999
Publications & Presentations
PubMed
- 3 citationsLarge-scale surveillance study of the safety and effectiveness of entecavir in Korean patients with chronic hepatitis B.Chang Wook Kim, Chang Seop Kim, Hee Yeon Kim, Chang Don Lee, Kyungha Yu
The Korean Journal of Internal Medicine. 2018-01-01 - 29 citationsSafety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HI...Javier Morales-Ramirez, Johannes R. Bogner, Jean-Michel Molina, Johan Lombaard, Ira B. Dicker
Plos One. 2018-10-23 - 52 citationsSafety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE studyMax Lataillade, Jacob Lalezari, Michael J. Kozal, Judith A. Aberg, Gilles Pialoux
The Lancet. HIV. 2020-11-01
Journal Articles
- Fostemsavir in Adults with Multidrug-Resistant HIV-1 InfectionMichael Kozal, Edwin Dejesus, Cyril Llamoso, The New England Journal of Medicine
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
